These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 28385959)

  • 1. CRISPR-Cas: Adapting to change.
    Jackson SA; McKenzie RE; Fagerlund RD; Kieper SN; Fineran PC; Brouns SJ
    Science; 2017 Apr; 356(6333):. PubMed ID: 28385959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems.
    Mohanraju P; Makarova KS; Zetsche B; Zhang F; Koonin EV; van der Oost J
    Science; 2016 Aug; 353(6299):aad5147. PubMed ID: 27493190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biology and Applications of CRISPR Systems: Harnessing Nature's Toolbox for Genome Engineering.
    Wright AV; Nuñez JK; Doudna JA
    Cell; 2016 Jan; 164(1-2):29-44. PubMed ID: 26771484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CRISPRs: Protein Inhibitors of CRISPR-Cas Systems.
    Davidson AR; Lu WT; Stanley SY; Wang J; Mejdani M; Trost CN; Hicks BT; Lee J; Sontheimer EJ
    Annu Rev Biochem; 2020 Jun; 89():309-332. PubMed ID: 32186918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five big mysteries about CRISPR's origins.
    Ledford H
    Nature; 2017 Jan; 541(7637):280-282. PubMed ID: 28102279
    [No Abstract]   [Full Text] [Related]  

  • 6. Structural plasticity and in vivo activity of Cas1 from the type I-F CRISPR-Cas system.
    Wilkinson ME; Nakatani Y; Staals RH; Kieper SN; Opel-Reading HK; McKenzie RE; Fineran PC; Krause KL
    Biochem J; 2016 Apr; 473(8):1063-72. PubMed ID: 26929403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cas1 and Cas2 From the Type II-C CRISPR-Cas System of
    He Y; Wang M; Liu M; Huang L; Liu C; Zhang X; Yi H; Cheng A; Zhu D; Yang Q; Wu Y; Zhao X; Chen S; Jia R; Zhang S; Liu Y; Yu Y; Zhang L
    Front Cell Infect Microbiol; 2018; 8():195. PubMed ID: 29951376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How type II CRISPR-Cas establish immunity through Cas1-Cas2-mediated spacer integration.
    Xiao Y; Ng S; Nam KH; Ke A
    Nature; 2017 Oct; 550(7674):137-141. PubMed ID: 28869593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas adaptation: insights into the mechanism of action.
    Amitai G; Sorek R
    Nat Rev Microbiol; 2016 Feb; 14(2):67-76. PubMed ID: 26751509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classification and evolution of type II CRISPR-Cas systems.
    Chylinski K; Makarova KS; Charpentier E; Koonin EV
    Nucleic Acids Res; 2014 Jun; 42(10):6091-105. PubMed ID: 24728998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adapting to new threats: the generation of memory by CRISPR-Cas immune systems.
    Heler R; Marraffini LA; Bikard D
    Mol Microbiol; 2014 Jul; 93(1):1-9. PubMed ID: 24806524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fidelity of prespacer capture and processing is governed by the PAM-mediated interactions of Cas1-2 adaptation complex in CRISPR-Cas type I-E system.
    Yoganand KN; Muralidharan M; Nimkar S; Anand B
    J Biol Chem; 2019 Dec; 294(52):20039-20053. PubMed ID: 31748409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptation in CRISPR-Cas Systems.
    Sternberg SH; Richter H; Charpentier E; Qimron U
    Mol Cell; 2016 Mar; 61(6):797-808. PubMed ID: 26949040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the Origin of Reverse Transcriptase-Using CRISPR-Cas Systems and Their Hyperdiverse, Enigmatic Spacer Repertoires.
    Silas S; Makarova KS; Shmakov S; Páez-Espino D; Mohr G; Liu Y; Davison M; Roux S; Krishnamurthy SR; Fu BXH; Hansen LL; Wang D; Sullivan MB; Millard A; Clokie MR; Bhaya D; Lambowitz AM; Kyrpides NC; Koonin EV; Fire AZ
    mBio; 2017 Jul; 8(4):. PubMed ID: 28698278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unravelling the structural and mechanistic basis of CRISPR-Cas systems.
    van der Oost J; Westra ER; Jackson RN; Wiedenheft B
    Nat Rev Microbiol; 2014 Jul; 12(7):479-92. PubMed ID: 24909109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct CRISPR spacer acquisition from RNA by a natural reverse transcriptase-Cas1 fusion protein.
    Silas S; Mohr G; Sidote DJ; Markham LM; Sanchez-Amat A; Bhaya D; Lambowitz AM; Fire AZ
    Science; 2016 Feb; 351(6276):aad4234. PubMed ID: 26917774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The roles of CRISPR-Cas systems in adaptive immunity and beyond.
    Barrangou R
    Curr Opin Immunol; 2015 Feb; 32():36-41. PubMed ID: 25574773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meet the Anti-CRISPRs: Widespread Protein Inhibitors of CRISPR-Cas Systems.
    Hwang S; Maxwell KL
    CRISPR J; 2019 Feb; 2(1):23-30. PubMed ID: 31021234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutting it close: CRISPR-associated endoribonuclease structure and function.
    Hochstrasser ML; Doudna JA
    Trends Biochem Sci; 2015 Jan; 40(1):58-66. PubMed ID: 25468820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clustered regularly interspaced short palindromic repeats (CRISPRs): the hallmark of an ingenious antiviral defense mechanism in prokaryotes.
    Al-Attar S; Westra ER; van der Oost J; Brouns SJ
    Biol Chem; 2011 Apr; 392(4):277-89. PubMed ID: 21294681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.